Telesis Bio Announces Commercial Release of BioXp® NGS Library Prep Kit for WGS
28 Setembro 2023 - 4:48PM
Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic
and synthetic biology solutions, today announced the commercial
release of its BioXp® NGS Library Prep kit for Whole Genome
Sequencing on the BioXp 3250 and BioXp 9600 systems. This NGS
library prep kit enables on-demand and automated library
preparation of up to 96 genomic DNA samples for use in whole genome
sequencing applications.
This new automation capability expands the suite
of NGS Library Preparation solutions on the BioXp platform and is
expected to enable researchers to reduce hands-on time and cost,
while streamlining the NGS Library Preparation workflow,
accelerating time to answer in genomics discovery workflows.
“This kit builds on the versatility of the BioXp®
platform providing customers with an efficient solution for
advancing genomics applications. Earlier this year we launched our
first NGS Library Prep kit for Plasmid sequencing to streamline the
workflow from synthesis to analysis.
“With this addition, we strengthen our portfolio
of automated solutions for driving efficiency and speed in
synthesis and molecular biology applications throughout
therapeutics discovery. The BioXp platforms’ core automated
workflows for DNA and mRNA synthesis beginning from the customer’s
sequence, linear DNA, or plasmid DNA offer a variety of rapid,
push-button automation solutions for overcoming workflow
bottlenecks and driving efficiency in labs around the world. We
believe this total automated solution provides a powerful tool for
researchers to gain workflow control and seamlessly integrate
genomics and molecular biology in workflows throughout discovery,”
said Todd R. Nelson, Ph.D., CEO and Founder of Telesis Bio.
For more information on BioXp® NGS Library Prep
Kits please visit:
https://telesisbio.com/products/bioxp-kits/ngs/
About Telesis Bio Telesis Bio is
empowering scientists with the ability to create novel, synthetic
biology-enabled solutions for many of humanity’s greatest
challenges. As inventors of the industry-standard Gibson Assembly®
method and the first commercial automated benchtop DNA and mRNA
synthesis system, Telesis Bio is enabling rapid, accurate and
reproducible writing of DNA and mRNA for numerous downstream
markets. The award-winning BioXp® systems consolidate, automate,
and optimize the entire synthesis, cloning and amplification
workflow. As a result, they deliver virtually error-free synthesis
of DNA and RNA at scale within days and hours instead of weeks or
months. Scientists around the world are using the technology in
their own laboratories to accelerate the design-build-test paradigm
for novel, high-value products for precision medicine, biologics
drug discovery, vaccine and therapeutic development, genome
editing, and cell and gene therapy. Telesis Bio is a public company
based in San Diego. For more information, visit
www.telesisbio.com.
Telesis Bio, the Telesis Bio logo, Gibson
Assembly, and BioXp are trademarks of Telesis Bio Inc.
Forward-Looking Statements
This press release contains forward-looking
statements. All statements other than statements of historical
facts contained herein are forward-looking statements reflecting
the current beliefs and expectations of management made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. These statements include statements and
guidance regarding Telesis Bio’s future financial performance as
well as statements regarding the future release and success of new
and existing products and services. Such statements are based on
current assumptions that involve risks and uncertainties that could
cause actual outcomes and results to differ materially. These risks
and uncertainties, many of which are beyond our control, include
risks described in the section entitled Risk Factors and elsewhere
in our Quarterly Report on Form 10-Q, which was filed with the
Securities and Exchange Commission on August 11, 2023. These
forward-looking statements speak only as of the date hereof and
should not be unduly relied upon. Telesis Bio disclaims any
obligation to update these forward-looking statements.
Contact: Jen Carroll Vice President of Investor
Relations jen.carroll@telesisbio.com
Telesis Bio (NASDAQ:TBIO)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Telesis Bio (NASDAQ:TBIO)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024